Tocilizumab or TNF inhibitors in RA?

被引：3
|
作者：
Leake I. [1 ]
机构：
[1] Nature Reviews Rheumatology,
来源：
Nature Reviews Rheumatology | 2018年 / 14卷 / 7期
关键词：
D O I：
10.1038/s41584-018-0031-7
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：384 / 384
相关论文
共 50 条
  • [21] Effectiveness of TNF inhibitors (TNF-I) in biologic naive and switched RA patients in a US cohort
    Greenberg, J.
    Gibofsky, A.
    Reed, G.
    Decktor, D.
    Dehoratius, R.
    Kremer, J.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S524 - S525
  • [22] Impact of Tocilizumab Therapy After Switching From Tumor Necrosis Factor (TNF) inhibitors - Prevention of Joint Damage by Tocilizumab in Patients with Inadequate Response to Anti-TNF Therapies
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Amano, Koichi
    Sato, Eri
    Nawata, Masao
    Nagasawa, Hayato
    Hoshi, Daisuke
    Saito, Kazuyoshi
    Fukuyo, Shunsuke
    Hanami, Kentaro
    Kameda, Hideto
    Kurasawa, Takahiko
    Kaneko, Yuko
    Yamanaka, Hisashi
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S484 - S484
  • [23] Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?
    Torsten Witte
    Clinical Rheumatology, 2015, 34 : 629 - 634
  • [24] Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?
    Witte, T.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 (03): : 279 - +
  • [25] OVERALL CANCER RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS, TOCILIZUMAB, ABATACEPT, OR RITUXIMAB
    Wadstrom, H.
    Frisell, T.
    Askling, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 93 - 93
  • [26] Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?
    Witte, Torsten
    CLINICAL RHEUMATOLOGY, 2015, 34 (04) : 629 - 634
  • [27] CLINICAL EFFICACY OF TNF INHIBITORS AND ABATACEPT IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS SWITCHING FROM TOCILIZUMAB
    Hirabara, S.
    Kojima, T.
    Takahashi, N.
    Yabe, Y.
    Kaneko, A.
    Kida, D.
    Hirano, Y.
    Ishiguro, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1057 - 1058
  • [28] Treatment of rheumatoid Arthritis in Practice - a Comparison of Tocilizumab vs. TNF-Inhibitors (CONSENS)
    Backhaus, M.
    Kaufmann, J.
    Richter, C.
    Vollmer, M.
    Volberg, C.
    Wassenberg, S.
    Roske, A.
    Hellmann, P.
    Gaubitz, M.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 119 - 120
  • [29] RETENTION OF TOCILIZUMAB AS MONOTHERAPY VERSUS TNF INHIBITORS WITH CONVENTIONAL SYNTHETIC DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TNF INHIBITORS: A STUDY FROM THE TOCERRA COLLABORATION
    Lauper, K.
    Nordstrom, D. C.
    Pavelka, K.
    Hernandez, V.
    Santos, M. J.
    Rotar, Z.
    Iannone, F.
    Codreanu, C.
    Lukina, G.
    Gale, S. L.
    Sarsour, K.
    Pethoe-Schramm, A.
    Courvoisier, D. S.
    Gabay, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 850 - 851
  • [30] Direct cost of patients on TNF-α inhibitors for the treatment of rheumatoid arthritis (RA).
    Kerney, D
    Ollendorf, D
    Yu, EB
    Woolley, JM
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S509 - S509
12345